ovarian cancer

GSK ESMO
Biotech

GSK CEO’s ‘scientific courage’ propels ADC toward ph. 3 tests

When Fierce last caught up with GSK’s head of oncology R&D, we were told to “stay tuned” for hotly anticipated data on a pair of ADCs.
James Waldron Apr 12, 2026 10:10am
Make a delay and accumulation of outstanding tasks Full stop

Accent halts DHX9 inhibitor trial over adverse events

Feb 26, 2026 5:01am
pause halt pause button

FDA freezes enrollment in MacroGenics cancer trial after death

Feb 24, 2026 2:00pm
On target clinical trial success bullseye score

Corcept racks up ph. 3 cancer win to bounce back from FDA blow

Jan 22, 2026 9:45am
An arrow incrementally going up stairs before pointing straight up Blue background

ESMO: Daiichi, Merck move ovarian cancer ADC toward pivotal test

Oct 20, 2025 10:45am
Cancer mutation precision medicine oncology targeted

ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR

Oct 19, 2025 4:15am